INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

Accessibility StatementSkip Navigation [Click here for information about joining the class action] Attorney advertising. Prior results do not guarantee similar outcomes. On August 25, 2025, Axogen issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025." CONTACT:Danielle PeytonPomerantz LLP[email protected] ...